Review



plasma cfdna concentration  (NEN Life Science)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    NEN Life Science plasma cfdna concentration
    Plasma <t>cfDNA</t> concentration ( A ), cfDNA <t>Alu</t> <t>hypomethylation</t> ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.
    Plasma Cfdna Concentration, supplied by NEN Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+cfdna+concentration/plasma+cfdna+concentration/pmc08870292-173-4-12
    Average 90 stars, based on 1 article reviews
    plasma cfdna concentration - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias"

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    Journal: Cancers

    doi: 10.3390/cancers14041025

    Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.
    Figure Legend Snippet: Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.

    Techniques Used: Clinical Proteomics, Concentration Assay, Control, MANN-WHITNEY

    Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
    Figure Legend Snippet: Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Techniques Used: Clinical Proteomics, Concentration Assay

    Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).
    Figure Legend Snippet: Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).

    Techniques Used: Concentration Assay

    Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.
    Figure Legend Snippet: Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.

    Techniques Used: Clinical Proteomics, Concentration Assay

    ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .
    Figure Legend Snippet: ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Techniques Used: Clinical Proteomics, Concentration Assay

    Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .
    Figure Legend Snippet: Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Techniques Used: Concentration Assay

    Related Articles

    Clinical Proteomics:

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: However, hypomethylation revealed a very high and significant AUC of 0.874 (95% CI, 0.77–0.98; p = 0.004) for the presence of an advanced tumor as compared to the cured patients with the highest accuracy obtained at a cutoff > 1.135%, which corresponded to a sensitivity and specificity for the presence of an advanced NEN of 79.6% and 88.9%, respectively ( B). .. When a combination of plasma cfDNA concentration, hypomethylation, and cfDNA integrity were used for the multiple logistic regression ROC analysis, the diagnostic power to discriminate patients with advanced NEN from healthy controls, the AUC was calculated with 0.694 (95% CI, 0.58 to 0.81; p = 0.0038) with a positive predictive value (PPV) of 70.3% and negative predictive value (NPV) of 55.6% at the chosen classification cutoff of 0.5 ( A). ..

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: .. In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease. ..

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: .. The ROC curve analysis for plasma cfDNA concentration was able to distinguish between metastatic NEN patients and healthy individuals with an estimated AUC of 0.691 (95% CI, 0.58 to 0.80; p = 0.0044) with a sensitivity of 81.1% and a specificity of 41.4% at the chosen cutoff point of > 0.6 pg/μL. ..

    Concentration Assay:

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: However, hypomethylation revealed a very high and significant AUC of 0.874 (95% CI, 0.77–0.98; p = 0.004) for the presence of an advanced tumor as compared to the cured patients with the highest accuracy obtained at a cutoff > 1.135%, which corresponded to a sensitivity and specificity for the presence of an advanced NEN of 79.6% and 88.9%, respectively ( B). .. When a combination of plasma cfDNA concentration, hypomethylation, and cfDNA integrity were used for the multiple logistic regression ROC analysis, the diagnostic power to discriminate patients with advanced NEN from healthy controls, the AUC was calculated with 0.694 (95% CI, 0.58 to 0.81; p = 0.0038) with a positive predictive value (PPV) of 70.3% and negative predictive value (NPV) of 55.6% at the chosen classification cutoff of 0.5 ( A). ..

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: .. In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease. ..

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: .. The ROC curve analysis for plasma cfDNA concentration was able to distinguish between metastatic NEN patients and healthy individuals with an estimated AUC of 0.691 (95% CI, 0.58 to 0.80; p = 0.0044) with a sensitivity of 81.1% and a specificity of 41.4% at the chosen cutoff point of > 0.6 pg/μL. ..

    Diagnostic Assay:

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias
    Article Snippet: However, hypomethylation revealed a very high and significant AUC of 0.874 (95% CI, 0.77–0.98; p = 0.004) for the presence of an advanced tumor as compared to the cured patients with the highest accuracy obtained at a cutoff > 1.135%, which corresponded to a sensitivity and specificity for the presence of an advanced NEN of 79.6% and 88.9%, respectively ( B). .. When a combination of plasma cfDNA concentration, hypomethylation, and cfDNA integrity were used for the multiple logistic regression ROC analysis, the diagnostic power to discriminate patients with advanced NEN from healthy controls, the AUC was calculated with 0.694 (95% CI, 0.58 to 0.81; p = 0.0038) with a positive predictive value (PPV) of 70.3% and negative predictive value (NPV) of 55.6% at the chosen classification cutoff of 0.5 ( A). ..



    Similar Products

    plasma cfdna concentration  (NEN Life Science)
    90
    NEN Life Science plasma cfdna concentration
    Plasma <t>cfDNA</t> concentration ( A ), cfDNA <t>Alu</t> <t>hypomethylation</t> ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.
    Plasma Cfdna Concentration, supplied by NEN Life Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+cfdna+concentration/plasma+cfdna+concentration/pmc08870292-173-4-12
    Average 90 stars, based on 1 article reviews
    plasma cfdna concentration - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    plasma cell free dna concentration  (Thermo Fisher)
    99
    Thermo Fisher plasma cell free dna concentration
    Plasma <t>cfDNA</t> concentration ( A ), cfDNA <t>Alu</t> <t>hypomethylation</t> ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.
    Plasma Cell Free Dna Concentration, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasma+cfdna+concentration/DNA/pmc07010551-134-17-24
    Average 99 stars, based on 1 article reviews
    plasma cell free dna concentration - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: Plasma cfDNA concentration ( A ), cfDNA Alu hypomethylation ( B ), and LINE-1 cfDNA integrity ( C ) in the healthy control group (green) and patients with metastatic NEN (grey). Deceased patients are marked in red, patients lost to follow-up in black. * p < 0.05; ** p < 0.005 in the Mann–Whitney U-test.

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Clinical Proteomics, Concentration Assay, Control, MANN-WHITNEY

    Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: Plasma cfDNA concentration ( A ), cfDNA hypomethylation ( B ), and cfDNA integrity ( C ) with respect to tumor burden (no tumor, low, moderate, or high tumor burden) * p < 0.05.; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Clinical Proteomics, Concentration Assay

    Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: Receiver operating characteristic (ROC) curves to distinguish between healthy controls and patients with advanced NEN disease ( A ) and between presumably cured NEN patients and patients with advanced NEN ( B ) for cfDNA concentration ( left ), percentage of cfDNA hypomethylation ( middle ), and cfDNA integrity ( right ).

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Concentration Assay

    Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: Multiparametric ROC analysis using plasma cfDNA concentration, percentage of cfDNA hypomethylation, and cfDNA integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients with advanced disease or between ( B ) presumably cured NEN patients and patients with advanced NEN disease.

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Clinical Proteomics, Concentration Assay

    ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: ROC analysis of plasma cfDNA concentration ( A , B ), Alu hypomethylation ( C , D ), and LINE-1 integrity ( E , F ) for distinguishing healthy controls ( A , C , E ), or cured patients ( B , D , F ) from patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Clinical Proteomics, Concentration Assay

    Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Journal: Cancers

    Article Title: Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias

    doi: 10.3390/cancers14041025

    Figure Lengend Snippet: Multiparametric ROC analysis using cfDNA concentration, percentage of Alu hypomethylation, and LINE-1 integrity to estimate the strength of the model to discriminate between ( A ) healthy controls and NEN patients or ( B ) presumably cured NEN patients and patients with low, moderate, and high tumor burden (TB), along with the area under the curve (AUC), for sensitivities and specificities see .

    Article Snippet: In conclusion, we found plasma cfDNA concentration, integrity, and hypomethylation in metastatic NEN patients to be very promising and easy to assess parameters for a “liquid biopsy” to evaluate patients with neuroendocrine neoplasms during the course of their disease.

    Techniques: Concentration Assay